DK0903148T3 - Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion - Google Patents

Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion

Info

Publication number
DK0903148T3
DK0903148T3 DK98306332T DK98306332T DK0903148T3 DK 0903148 T3 DK0903148 T3 DK 0903148T3 DK 98306332 T DK98306332 T DK 98306332T DK 98306332 T DK98306332 T DK 98306332T DK 0903148 T3 DK0903148 T3 DK 0903148T3
Authority
DK
Denmark
Prior art keywords
infection
patients
combination therapy
chronic hepatitis
hcv rna
Prior art date
Application number
DK98306332T
Other languages
Danish (da)
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0903148(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0903148T3 publication Critical patent/DK0903148T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK98306332T 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion DK0903148T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22

Publications (1)

Publication Number Publication Date
DK0903148T3 true DK0903148T3 (da) 2001-12-17

Family

ID=27130070

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01113628T DK1136075T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
DK98306332T DK0903148T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01113628T DK1136075T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Country Status (24)

Country Link
EP (3) EP1136075B1 (de)
JP (1) JPH11152231A (de)
KR (1) KR20010024188A (de)
CN (1) CN1250283C (de)
AR (1) AR013497A1 (de)
AT (2) ATE206618T1 (de)
AU (1) AU749924B2 (de)
BR (1) BR9812484A (de)
CA (1) CA2245938C (de)
CO (1) CO4970691A1 (de)
DE (2) DE69801970T2 (de)
DK (2) DK1136075T3 (de)
ES (2) ES2162393T3 (de)
HK (2) HK1016505A1 (de)
HU (1) HUP0100092A3 (de)
IL (1) IL134428A0 (de)
MY (1) MY117781A (de)
NO (1) NO20001437L (de)
NZ (1) NZ502740A (de)
PE (1) PE119199A1 (de)
PT (1) PT903148E (de)
SK (1) SK3922000A3 (de)
TW (1) TW568787B (de)
WO (1) WO1999015194A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5281726B2 (ja) * 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
AR022116A1 (es) * 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DK1330468T3 (da) 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
RU2371195C2 (ru) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Способ лечения вирусных инфекций
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Nukleosidanaloga
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
GB2506085A (en) 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SI2950786T1 (sl) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
CO4970691A1 (es) 2000-11-07
DE69801970T2 (de) 2002-06-13
ATE206618T1 (de) 2001-10-15
EP1136075B1 (de) 2003-01-15
NO20001437D0 (no) 2000-03-20
DE69810822T2 (de) 2003-11-20
SK3922000A3 (en) 2000-10-09
CA2245938A1 (en) 1999-03-21
TW568787B (en) 2004-01-01
ES2186660T3 (es) 2003-05-16
AU749924B2 (en) 2002-07-04
PE119199A1 (es) 1999-12-01
HUP0100092A3 (en) 2002-03-28
NO20001437L (no) 2000-03-20
MY117781A (en) 2004-08-30
AR013497A1 (es) 2000-12-27
IL134428A0 (en) 2001-04-30
KR20010024188A (ko) 2001-03-26
ATE230999T1 (de) 2003-02-15
AU9473798A (en) 1999-04-12
EP1317929A2 (de) 2003-06-11
CN1271292A (zh) 2000-10-25
ES2162393T3 (es) 2001-12-16
JPH11152231A (ja) 1999-06-08
HK1041440A1 (en) 2002-07-12
BR9812484A (pt) 2000-09-19
PT903148E (pt) 2002-02-28
DE69801970D1 (de) 2001-11-15
DE69810822D1 (de) 2003-02-20
WO1999015194A1 (en) 1999-04-01
HUP0100092A2 (hu) 2001-05-28
EP0903148A3 (de) 1999-04-28
NZ502740A (en) 2002-10-25
EP1317929A3 (de) 2003-07-02
DK1136075T3 (da) 2003-04-28
EP0903148A2 (de) 1999-03-24
HK1041440B (zh) 2003-09-05
CA2245938C (en) 2003-07-15
EP1136075A1 (de) 2001-09-26
EP0903148B1 (de) 2001-10-10
CN1250283C (zh) 2006-04-12
HK1016505A1 (en) 1999-11-05

Similar Documents

Publication Publication Date Title
DK0903148T3 (da) Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion
NO20005755L (no) Kombinasjonsterapi omfattende ribavirin og interferon-<alfa> hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
ATE517070T1 (de) Gipsplatten mit erhöhter widerstandsfähigkeit gegen dauerhafte verformung
GB2341804B (en) Improvements in or relating to hypodermic syringes
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
NO20011789L (no) Ribavirin-interferon <alfa> kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
FI962771A0 (fi) Absorboiva esine, jolla on sisääntaivutetut kalvosimet
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EE200100481A (et) Taimes viirusresistentsuse tekitamise meetod
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
NO20010190D0 (no) Salformet stol
ATE251855T1 (de) Herrenunterhose mit schutzstruktur